Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Oct;8(5):601-8.
doi: 10.1177/1740774511418848. Epub 2011 Sep 15.

Challenges in the design and analysis of non-inferiority trials: a case study

Valerie Durkalski  1 , Robert Silbergleit, Daniel Lowenstein
Affiliations

Challenges in the design and analysis of non-inferiority trials: a case study

Valerie Durkalski et al. Clin Trials. 2011 Oct.

Abstract

Background: The literature on the design, conduct, and analysis of non-inferiority trials is continuously evolving. Several design issues continue to be researched including the choice of active control, choice of non-inferiority margin, and optimal analytic approaches. To date, there has been relatively little in the literature documenting actual experiences with implementing available methodology for non-inferiority trials.

Purpose: This article serves as a case study and highlights some of the challenges encountered in the design of a Phase III non-inferiority trial in status epilepticus that is being conducted under a Food and Drug Administration Investigational New Drug Application (IND).

Methods: The IND application was put on clinical hold by the Food Drug and Administration due to concerns with the design. Specifically, support for the active control, non-inferiority margin, and overall interpretability of trial results were questioned, and a recommendation was made to consider a superiority design. The authors describe their interactions with the Food Drug and Administration and their application of available methods and approaches to address these concerns.

Results: The investigators' response to the clinical hold provided detailed information to support the conduct of a non-inferiority trial. The study team received Food Drug and Administration approval to initiate the trial in October 2008. The trial enrollment began in June 2009 and is being conducted by roughly 800 paramedic units in over 40 Emergency Medicine Service systems across the United States.

Limitations: There is still a great deal of methodological research needed to fully understand the application and impact of the non-inferiority trial design.

Conclusions: It is evident that non-inferiority trials have an important place in clinical trial design and analysis. These trials may be the only way and only opportunity to answer certain questions; so, they must be designed and conducted with rigor. This case study is an attempt to share our experiences in implementation.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Effect of IV Lorazepam, Placebo or Active Control in Acute Seizures Studies (marker (●) size indicates sample size)
See this image and copyright information in PMC

References

    1. Blackwelder WC. Proving the Null Hypothesis in Clinical Trials. Controlled Clinical Trials 1982; 3:345–353. - PubMed
    1. Jones P, Jarvis P, Lewis JA, Ebbutt AF. Trials to Assess Equivalence: the importance of rigorous methods. BMJ 1996; 313:36–39. - PMC - PubMed
    1. Ebbutt AF, Frith L. Practical Issues in Equivalence Trials. Statistics in Medicine 1998; 17:1691–1702. - PubMed
    1. Hauck W and Anderson S. Some Issues in the Design and Analysis of Equivalence Trials. Drug Information Journal 1999; 33: 109–118.
    1. Laster L and Johnson M. Non-inferiority trials: the ‘at least as good as’ criterion. Statistics in Medicine 2003; 22:187–200. - PubMed

Publication types

LinkOut - more resources